Who
Michael S. Wyzga
Director
Company insider
Files Form 4 as: Director, Tvardi Therapeutics; Director, Mereo BioPharma Group; Director, X4 Pharmaceuticals; Director, Invivyd; Director, LogicBio Therapeutics; Director, Exact Sciences; Director, OncoMed Pharmaceuticals; Director, Akebia Therapeutics.
In numbers
- Trades disclosed
- 121
- Buys
- 2
- Sells
- 8
- Bought
- $56K
- Sold
- $6.6M
- Companies
- 12
- Companies where not an officer
- 10
- First trade
- 25 May 2006
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,000 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,000 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | XFOR X4 Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 9 Jun 2025filed 10 Jun 2025 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 17 Apr 2025filed 21 Apr 2025 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 15 Apr 2025filed 17 Apr 2025 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,441 | filing |
| 5 Feb 2025filed 6 Feb 2025 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 5 Feb 2025filed 6 Feb 2025 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,487 | filing |
| 17 Jun 2024filed 17 Jun 2024 | MREO Mereo BioPharma GroupBiotechnology | SEC FORM 4 Code A | $100K25,050 at $3.99 | filing |
| 10 Jun 2024filed 11 Jun 2024 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 8 Feb 2024filed 9 Feb 2024 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 8 Feb 2024filed 9 Feb 2024 | MREO Mereo BioPharma Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,783 | filing |
| 18 Aug 2023filed 22 Aug 2023 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $30K25,000 at $1.20 | filing |
| 13 Jun 2023filed 14 Jun 2023 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 23 May 2023filed 25 May 2023 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 16 Nov 2022filed 17 Nov 2022 | LogicBio Therapeuticsoption or derivative | SEC FORM 4 Code D | —12,500 | filing |
| 16 Nov 2022filed 17 Nov 2022 | LogicBio Therapeutics | SEC FORM 4 Code D | —3,141 | filing |
News
Insider Buying: X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Acquires $11,868.00 in StockXFOR · tickerreport.com · 22 Oct 2026Analyzing Akebia Therapeutics (NASDAQ:AKBA) and Pharming Group (NASDAQ:PHAR)AKBA · tickerreport.com · 18 Oct 2026
0 headlines in the last 90 days name Michael S. Wyzga; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.